Eli Lilly and Company discovers, develops, and markets pharmaceutical products worldwide. The company focuses on diabetes, oncology, immunology, and neuroscience, with leading products including Mounjaro, Verzenio, and Trulicity.
Eli Lilly and Company operates in the Healthcare sector and is a constituent of the S&P 500 index. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for LLY.
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). LLY Stock Intelligence Report. [stoxpulse.com/stocks/lly]
Disclaimer: The information on this page about Eli Lilly and Company (LLY) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Eli Lilly and Company.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
Earnings beat by 38%
Jun 30
Hernandez sold 13 shares
3d ago
Dozier sold 216 shares
3d ago
Eli Lilly Stock Is Not Done Growing Yet, But It's ...
4h ago
Lilly Launches Foundayo in the UK as NICE Review C...
5h ago
StoxPulse AI results for LLY: Pulse Score 48/100. Primary sentiment trends from 15 news sources and 20 SEC filings indicate a neutral outlook.
Market Cap
$1.08T
P/E Ratio
46.8
EPS
$7.39
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Sep 25
+22.0%
Dec 25
+11.9%
Mar 26
+27.0%
Jun 26
+38.1%
Beat estimates 4 of 4 quarters (100%)
Eli Lilly and Company discovers, develops, and markets pharmaceutical products worldwide. The company focuses on diabetes, oncology, immunology, and neuroscience, with leading products including Mounjaro, Verzenio, and Trulicity.
Eli Lilly Stock Is Not Done Growing Yet, But It's Due For Compression (Rating Downgrade)
Lilly Launches Foundayo in the UK as NICE Review Continues
Could Roche and Lilly’s Blood Test Make Alzheimer’s Assessment More Accessible?
Jim Cramer flagged one stock quietly concentrating portfolios
Dividend Champion, Contender, And Challenger Highlights: Week September 6
Whale's Insight: Rate Hike? 6 Reasons The Fed Holds In September
Novo Nordisk (CPSE:NOVO B) Stock Looks Below Fair Value But Faces Earnings Doubts
Was JNJ Stock Rally Actually Its Own?